

CLAIMS

1. Use of a composition comprising a monoclonal progastrin-binding antibody, or an antigen-binding fragment thereof, said antigen-binding fragment comprising 6 CDRs, in the manufacture of a medicament for the prevention or the treatment of gastric cancer,
- 5 wherein said monoclonal progastrin-binding antibody, or antigen-binding fragment thereof, specifically binds progastrin but does not bind gastrin-17 (G17), gastrin-34 (G34), glycine-extended gastrin-17 (G17-Gly) or glycine-extended gastrin-34 (G34-Gly),
- 10 wherein said progastrin antibody is an antibody selected from:
- an antibody comprising:
 - o a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N° 4, 5 and 6, respectively, and
 - o a light chain comprising CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N° 7, 8 and 9, respectively,
 - 15 - an antibody comprising:
 - o a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N° 10, 11 and 12, respectively, and
 - o a light chain comprising CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N° 13, 14 and 15, respectively,
 - 20 - an antibody comprising:
 - o a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N° 16, 17 and 18, respectively, and
 - o a light chain comprising CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N° 19, 20 and 21, respectively,
 - 25 - an antibody comprising:
 - o a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N° 22, 23 and 24, respectively, and
 - o a light chain comprising CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N° 25, 26 and 27, respectively,
 - 30 - an antibody comprising:

- o a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N° 28, 29 and 30, respectively, and
 - o a light chain comprising CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N° 31, 32 and 33, respectively, and
 - 5 - an antibody comprising:
 - o a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N° 34, 35 and 36, respectively, and
 - o a light chain comprising CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N° 37, 38 and 39, respectively.
- 10
- 2. The use of claim 1, wherein said monoclonal progastrin-binding antibody, or antigen-binding fragment thereof, is a humanized antibody.
- 3. The use of claim 2, wherein said monoclonal antibody also comprises constant regions of the light-chain and the heavy-chain derived from a human antibody.
- 15 4. The use of any one of claims 1 to 3, wherein said monoclonal progastrin-binding antibody, or an antigen-binding fragment thereof, is selected among N-terminal anti-progastrin antibodies and C-terminal anti-progastrin antibodies.
- 5. The use of any one of claims 1 to 4, wherein said monoclonal progastrin-binding antibody, or an antigen-binding fragment thereof, is a neutralizing
- 20 antibody.
- 6. The use of any one of claims 1 to 5, wherein said monoclonal progastrin-binding antibody, or an antigen-binding fragment thereof is conjugated to a cytotoxic molecule.
- 25 7. The use of any one of claims 1 to 6, wherein said gastric cancer is metastatic.

8. The use according to any one of claims 1 to 7, wherein said composition further comprises a pharmaceutically acceptable carrier.
9. The use of any one of claims 1 to 8, wherein said composition is to be administered with an anti-cancer therapeutic molecule chosen among: a
5 chemotherapeutic molecule and a targeted therapy molecule.
10. The use of claim 9, wherein said composition and said anti-cancer therapeutic molecule are to be administered simultaneously, sequentially or separately.
11. The use of claim 9 or 10, wherein said chemotherapeutic molecule is
10 chosen among folate antagonists, purine antagonists, pyrimidine antagonists, DNA alkylating molecules, DNA cross-linking drugs, antibiotics, platinum complexes, proteasome inhibitors, mitotic spindle poisons, topoisomerase inhibitors and tyrosine kinase inhibitors.
12. The use of any one of claims 9 to 11, wherein said targeted therapy
15 molecule is chosen among antibodies that target EGFR, such as cetuximab or panitumumab, antibodies that target VEGF, such as bevacizumab, antibodies that target HER2, such as trastuzumab or pertuzumab, antibodies that target PD-1 and PDL-1, such as pembrolizumab, antibodies that target CTLA-4, such as ipilimumab, small molecule drugs
20 that target EGFR, such as erlotinib, small molecule drugs that target BRAF, such as vemurafenib or dabrafenib and a recombinant fusion protein that target VEGF, such as Aflibercept.